Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy

Colquhoun, David, Chirovsky, Diana, Sazonov, Valsilisa, Cui, Yadong A. and Ambegaonkar, Baishali (2013) Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy. Experimental and Clinical Cardiology, 18 1: e32-e36.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
Author Colquhoun, David
Chirovsky, Diana
Sazonov, Valsilisa
Cui, Yadong A.
Ambegaonkar, Baishali
Title Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy
Journal name Experimental and Clinical Cardiology   Check publisher's open access policy
ISSN 1205-6626
Publication date 2013-03
Sub-type Article (original research)
Volume 18
Issue 1
Start page e32
End page e36
Total pages 5
Place of publication Canada
Publisher Pulsus Group
Collection year 2014
Language eng
Formatted abstract
BACKGROUND: Few studies have assessed the prevalence of mixed dyslipidemia (MD) and the effectiveness of lipid-modifying therapy (LMT) for the treatment of abnormal levels of low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) in Australian clinical practice. Objective: To estimate the prevalence of MD in Australian patients undergoing LMT.

METHODS: Patients 35 years of age and older undergoing LMT for ≥1 year were enrolled from nine general practice and cardiologist/endocrinologist outpatient clinics in Australia between April 2007 and May 2008. Lipid levels, including LDL-C, HDL-C and TG levels, were prospectively collected at the enrollment date and from patient records one year before LMT was initiated. Normal lipid levels were assessed according to Australian guidelines. Multivariate logistic regression was used to evaluate predictors of normal lipid level attainment.

RESULTS: Of 297 patients (mean age 60.1 years; 43% male), the prevalence of MD before LMT was 61%; 93% of patients had elevated LDL-C levels, 17% had low HDL-C levels and 62% had elevated TG levels. Following LMT (98.3% statins), 31% of patients had MD. The prevalence of elevated LDL-C levels, low HDL-C levels and elevated TG levels were 44%, 21% and 42%, respectively. Baseline lipid levels were significant predictors of attainment of normal LDL-C levels (OR 0.42 [95% CI 0.27 to 0.63]) and TG levels (OR 0.26 [95% CI 0.16 to 0.45]).

: Among Australian patients primarily treated with statins, nearly one-third had MD despite LMT. LMT considerably improved LDL-C goal attainment; however, a large proportion of patients did not achieve normal HDL-C and TG levels. Patients may benefit from a more comprehensive approach to lipid management that treats all three lipid risk factors, as suggested in clinical guidelines.
Keyword Australia
High-density lipoprotein cholesterol
Lipid modifying therapy
Low-density lipoprotein cholesterol
Density-Lipoprotein Cholesterol
Triglyceride-Rich Lipoproteins
Panel-Iii Guidelines
Statin Therapy
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 30 Jun 2013, 00:07:58 EST by System User on behalf of School of Medicine